Parameter | Cost | Distribution | Reference | ||
---|---|---|---|---|---|
First year | Maintenance | ||||
Fatal event | Non-fatal event | ||||
Micro-and macrovascular complications | |||||
Unstable angina | € 4557 | € 3090 | € 892 | Gamma | |
Myocardial infarction | € 10464 | € 7036 | € 892 | Gamma | |
Heart failure | € 4222 | € 3259 | € 3683 | Gamma | |
Stroke | € 6 660 | € 4738 | € 3725 | Gamma | |
End-stage kidney disease | € 53310 | € 53310 | € 28931 | Gamma | |
Blindness | - | € 2275 | € 834 | Gamma | |
Ulcers | - | € 5163 | € 402 | Gamma | |
Cost | Reference | ||||
Pharmacological treatment | |||||
Dapagliflozin | € 624.37 | Gamma | [22] | ||
Adverse events | |||||
Urinary tract infection | € 53 | Gamma | |||
Genital tract infection | € 53 | Gamma | |||
Diabetic ketoacidosis | € 3942 | Gamma | [24] | ||
Acute kidney failure | € 4151 | Gamma | [24] | ||
Fractures | € 4341 | Gamma | [29] | ||
Hypoglycemic events | |||||
Severe hypoglycemia | € 696 | Gamma | [30] | ||
Treatment discontinuation | € 52 | Gamma | [29] | ||
Chronic kidney disease | |||||
Stage 2 | € 1304 | Gamma | [31] | ||
Stage 3 | € 4860 | Gamma | [32] | ||
Stage 4 | € 8058 | Gamma | [33] | ||
Stage 5 | € 13659 | Gamma | [33] |